Sections on this page: Stock Price | Stock Charts | Company Profile | Earnings

VRTX Stock Price Today $154.63

 The recent VRTX stock price today is $154.63 +0.03 (0.02%) for Fri, Oct 20, 2017.

Year To Date

The Year To Date (YTD) return is +106.48%.

52 Week Low

The 52 Week Low stock price is 71.46 set on Thu, Dec 22, 2016 which is 305 days ago.

The current price per share is 116.39% above the 52 week low.

52 Week High

The 52 Week High stock price is $167.85 set on Tue, Jul 25, 2017 which is 90 days ago.

The current price per share is -7.88% below the 52 week high.

All Time High

The All Time High stock price is $167.85 set on Tue, Jul 25, 2017 which is 90 days ago.

The current price per share is -7.88% below the all time high.

Vertex Stock Charts

The 5 year and 1 year stock charts are below.

5 Year Stock Chart

The Vertex 5 year stock chart shows the historical prices over the previous 60 months.

VRTX 5 Year Stock Price Chart

1 Year Stock Chart

The Vertex 1 year stock chart shows the historical prices over the previous 12 months.

VRTX 1 Year Stock Price Chart

50 Day Moving Average

The 50 Day Moving Average is at $146.31 which is 5.69% below the stock price of $154.63.

200 Day Moving Average

The 200 Day Moving Average is at 109.99 which is 40.59% below the stock price of $154.63.

VRTX Company Profile

Vertex Pharmaceuticals Inc is a Health Care stock that trades on the NASDAQ and has a market capitalization of $38.99 Billion.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

For more information and analysis about Vertex Pharmaceuticals Inc, visit their web site at http://www.vpharm.com. For a real time price lookup on this ticker, VRTX, visit Google Finance and Bloomberg.

Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .

VRTX Earnings

 Below is the EPS, P/E Ratio and Earnings Date.

Earnings Per Share

The EPS is $1.04.

Price To Earnings Ratio

The P/E Ratio is 148.54%.

Earnings Dates

The Earnings Release Date was Wed, Jul 26, 2017.

Since this earnings release 89 days ago, the stock price is down by -4.53%.

2017-10-25 06:00:002017-10-25 13:00:00America/New_York0VRTX) Earnings , after the market close,Visit http://www.symbolsurfing.com/VRTX for more information.United StatesSymbol Surfing[email protected]

The next Earnings Release Date is, after the market close, on Wed, Oct 25, 2017, which is in 2 days.

Vertex Dividend

VRTX currently does not pay a dividend.